Loading...
XSHG603880
Market cap177mUSD
Dec 23, Last price  
4.54CNY
1D
-9.92%
1Q
26.82%
IPO
-30.17%
Name

Jiangsu Nanfang Medical Co Ltd

Chart & Performance

D1W1MN
XSHG:603880 chart
P/E
—
P/S
2.16
EPS
—
Div Yield, %
1.67%
Shrs. gr., 5y
0.05%
Rev. gr., 5y
4.57%
Revenues
600m
+10.03%
424,621,054510,798,291469,803,419433,022,478444,235,500488,708,743479,823,815491,688,0111,072,399,917527,440,662545,369,151600,095,343
Net income
-147m
35,767,10348,044,64553,380,20051,242,68651,980,39047,601,36739,250,11928,051,59598,067,61300-147,417,266
CFO
16m
-50.41%
76,074,46920,142,29873,518,72690,664,00699,350,00149,236,92652,749,49232,994,069154,122,592031,276,44815,509,531
Dividend
May 21, 20210.115385 CNY/sh
Earnings
Apr 18, 2025

Profile

Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal products, medical proof fabrics, adhesive tapes, bandages, sports protection products, first-aid kits, and care products in China and internationally. It offers medical adhesive tapes, medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, zinc oxide adhesive plasters, and masks, as well as customized products. The company was founded in 1990 and is based in Changzhou, China.
URL
https://www.nfmedical.com.cn/
IPO date
Aug 07, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
600,095
10.03%
545,369
3.40%
527,441
-50.82%
Cost of revenue
620,251
524,065
487,271
Unusual Expense (Income)
NOPBT
(20,155)
21,304
40,169
NOPBT Margin
3.91%
7.62%
Operating Taxes
(1,230)
Tax Rate
NOPAT
(18,925)
21,304
40,169
Net income
(147,417)
 
Dividends
(21,633)
(33,777)
Dividend yield
1.47%
1.61%
Proceeds from repurchase of equity
(1)
BB yield
0.00%
Debt
Debt current
452,034
456,276
352,344
Long-term debt
836
17,863
2,907
Deferred revenue
7,580
8,059
8,551
Other long-term liabilities
1
900
Net debt
295,481
285,752
142,687
Cash flow
Cash from operating activities
15,510
31,276
CAPEX
(66,160)
Cash from investing activities
(16,353)
Cash from financing activities
125,534
124,680
FCF
120,304
(69,038)
(242,517)
Balance
Cash
118,196
149,045
172,815
Long term investments
39,193
39,342
39,748
Excess cash
127,384
161,118
186,192
Stockholders' equity
330,229
500,735
534,148
Invested Capital
806,867
937,177
827,562
ROIC
2.41%
5.86%
ROCE
1.93%
3.95%
EV
Common stock shares outstanding
289,053
289,042
292,474
Price
5.09
-17.90%
6.20
-13.41%
7.16
-26.59%
Market cap
1,471,282
-17.90%
1,792,060
-14.42%
2,094,114
-26.66%
EV
1,771,714
2,082,635
2,241,913
EBITDA
36,824
62,916
69,209
EV/EBITDA
48.11
33.10
32.39
Interest
23,188
20,177
11,799
Interest/NOPBT
94.71%
29.37%